These data indicate that LLT1/CLEC2D might be an important player in SARS-CoV-2 mediated ARDS development in COVID-19 patients and may support our findings of LLT1 role in SARS-CoV-2-mediated immune response alterations. This evidence concerns the gene CLEC2D and COVID-19.